HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
ATAI
ATAI Life Sciences N.V.
Healthcare Biotechnology · New York, USA · Reports in usd
Market Cap: $2.67B
Market Cap
$2.67B
Enterprise Val
$2.45B
P/E Ratio
-4.00
P/B Ratio
15.16
Trailing PEG (1Y)
0.11
As Of
Aug 13, 2026

Overview & Key Metrics

Reporting period: Jun 30, 2026 · Q2 2026
Book Value$176.4M
Gross Margin100.00%
Profit Margin100.00%
Return on Equity-353.23%
Return on Assets-251.62%
Current Ratio8.58
Debt/Equity0.01
LT Debt/Equity0.01
Revenue Per Share0.00

Income Statement

Jun 30, 2026
Revenue$1.7M
Cost of Revenue$0.00
Gross Profit$1.7M
R&D$28.1M
SG&A$17.8M
Operating Expenses$45.8M
Operating Income-$44.1M
Interest Expense$0.00
Tax Expense$64.0K
Net Income-$32.5M
EPS (Basic)$-0.09
EPS (Diluted)$-0.09
EBIT-$32.5M
EBITDA-$32.2M
Consolidated Income-$32.5M
Non-Controlling Interests-$24.0K

Balance Sheet

Jun 30, 2026
Cash & Equivalents$168.8M
Accounts Receivable$0.00
Inventory$0.00
Current Assets$244.7M
LT Investments$5.9M
Property, Plant & Equipment$3.6M
Intangibles$3.0M
Non-Current Assets$20.0M
Total Assets$264.8M
Accounts Payable$11.5M
Current Debt$314.0K
Current Liabilities$28.5M
LT Debt$1.6M
Non-Current Liabilities$59.8M
Total Liabilities$88.4M
Total Debt$1.9M
Retained Earnings-$1.42B
Shareholder Equity$176.4M
Shares Outstanding368,166,674

Cash Flow Statement

Jun 30, 2026
Operating Cash Flow-$35.3M
Investing Cash Flow$158.6M
Financing Cash Flow$2.6M
CapEx$0.00
Free Cash Flow-$35.3M
Depreciation & Amort.$286.0K
Stock-Based Comp$7.4M
Acquisitions / Disposals$0.00
Investment Activity$158.6M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$2.6M
Dividends Paid$0.00
Net Change in Cash$125.7M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h